Breakdown of the Blood-Ocular Barrier as a Strategy for the Systemic Use of Nanosystems
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Several drug delivery systems have been proposed to overcome physiological barriers, improving ocular bioavailability. Systemic routes are seldom used due to the blood-ocular barrier. Novel drug delivery systems based on nanotechnology techniques have been developed to overcome ocular physiological barriers. This non-systematic review suggests the utilization of a transitory blood-ocular breakdown to allow the access of drugs by nanotechnology drug delivery systems via the systemic route. We discuss the possible ways to cause the breakdown of the blood-ocular barrier: acute inflammation caused by intraocular surgery, induced ocular hypotony, and the use of inflammatory mediators. The suitability of use of the systemic route and its toxic effects are also discussed in this article.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polyhydroxyethylaspartamide-based micelles for ocular drug delivery
Civiale, C., Licciardi, M., Cavallaro, G., Giammona, G., & Mazzone, M. G. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.05.028 · Cited by 120 · cited 2×
“Dexamethasone Micelles [57] Flurbiprofen Nanosuspension [58] Timolol maleate Discosomes [59] Pilocarpine nitrate Dexamethasone 2-hydroxypropyl-â-cyclodextrin [60,61]”
BackgroundCopland, D. A., Liu, J., Schewitz-Bowers, L. P., Brinkmann, V., Anderson, K., Nicholson, L. B., & Dick, A. D. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.10.008 · Cited by 50 · cited 2×
“have shown that Fingolimod (FTY720), a drug used in FDA phase III human multiple sclerosis trials, prevents T-cell migration to inflammatory sites by decreasing expression of the sphingosine-1 phosphate receptor generally required for egression from secondary lymphoid tissue [118].”
Background
Cited by
Nanotechnology-based strategies for treatment of ocular disease
Weng, Y., Liu, J., Jin, S., Guo, W., Liang, X., & Hu, Z. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.09.001 · Cited by 375
Lipid nanoparticles for the posterior eye segment
Bonilla, L., Espina, M., Severino, P., Cano, A., Ettcheto, M., Camins, A., García, M. L., Souto, E. B., & Sánchez-López, E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010090 · Cited by 76
Topical formulation of self-assembled antiviral prodrug nanomicelles for targeted retinal delivery
Mandal, A., Cholkar, K., Khurana, V., Shah, A., Agrahari, V., Bisht, R., Pal, D., & Mitra, A. K. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00128 · Cited by 60
Li, Z., Liu, M., Ke, L., Wang, L.-J., Wu, C., Li, C., Li, Z., & Wu, Y.-L. (2021) · Nanoscale Advances · doi:10.1039/d1na00596k · Cited by 59
Metadata
- Authors
- Occhiutto, M. L., Freitas, F. R., Maranhao, R. C., & Costa, V. P.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2012-05-14
- Volume
- 4
- Issue
- 2
- Pages
- 252-275
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W2100160646
- Cited by
- 108
- References
- 2
- FWCI
- 0.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Breakdown of the Blood-Ocular Barrier as a Strategy for the Systemic Use of Nanosystems. https://app.cochat.ai/papers/10.3390/pharmaceutics4020252
- The paper
- Occhiutto, M. L., Freitas, F. R., Maranhao, R. C., & Costa, V. P. (2012). Breakdown of the Blood-Ocular Barrier as a Strategy for the Systemic Use of Nanosystems. Pharmaceutics. https://doi.org/10.3390/pharmaceutics4020252
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.